Fatma Ataman

Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)

Oscar Matzinger, Irma Heimsoth, Philip Poortmans et al. · Acta Oncologica · 2010 · 116 citations · Full text

Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: Dummy run and individual case review

Oscar Matzinger, Philip Poortmans, Jean-Yves Giraud et al. · Radiotherapy and Oncology · 2008 · 58 citations

Urology, Quality Assurance, Genitourinary Cancer +10

Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863

Fatma Ataman, Alfredo Zurlo, Xavier Artignan et al. · European Journal of Cancer · 2004 · 47 citations

Urology, Radiation Medicine, Radiation Therapy +7

Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review

Fatma Ataman, Philip Poortmans, Roger Stupp et al. · European Journal of Cancer · 2004 · 36 citations

Neuro-oncology, Quality Assurance, Radiation Therapy +9

Quality assurance in the EORTC phase III randomised ‘boost vs. no boost’ trial for breast conserving therapy: Comparison of the results of two individual case reviews performed early and late during the accrual period

Philip Poortmans, Fatma Ataman, J.B. Davis et al. · Radiotherapy and Oncology · 2005 · 25 citations

Nursing, Surgical Oncology, Oncology +13